Protagenic Therapeutics, Inc.
PTIX
$0.218
-$0.0001-0.05%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 268.43% | -6.43% | 47.46% | -29.06% | -49.59% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 35.56% | -54.45% | 45.78% | 135.14% | 84.84% |
| Operating Income | -35.56% | 54.45% | -45.78% | -135.14% | -84.84% |
| Income Before Tax | 7.31% | 54.12% | -32.81% | -140.12% | -178.72% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 7.31% | 54.12% | -32.81% | -140.12% | -178.72% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 7.31% | 54.12% | -32.81% | -140.12% | -178.72% |
| EBIT | -35.56% | 54.45% | -45.78% | -135.14% | -84.84% |
| EBITDA | -37.53% | 55.29% | -44.69% | -133.47% | -80.79% |
| EPS Basic | 34.21% | 56.12% | -29.47% | -133.79% | -174.07% |
| Normalized Basic EPS | 0.96% | 56.06% | -48.16% | -135.24% | -93.50% |
| EPS Diluted | 34.21% | 56.12% | -29.14% | -129.41% | -174.07% |
| Normalized Diluted EPS | 0.96% | 56.06% | -48.16% | -135.24% | -93.50% |
| Average Basic Shares Outstanding | 40.90% | 4.57% | 2.59% | 2.71% | 1.68% |
| Average Diluted Shares Outstanding | 40.90% | 4.57% | 2.59% | 2.71% | 1.68% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |